• Explore /
  • Poster
  • / A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas.

A first-in-human, phase I, open-label study of a novel cancer vaccine labvax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas.

Abstract Poster

Authors

null

Weijie Ma

University of California Davis Comprehensive Cancer Center, Sacramento, CA

Weijie Ma , Shuai Chen , Nancy L. Ogihara , Jasmine Huynh , Ariel Yen , Karen Kelly , Primo "Lucky" N. Lara Jr., James A. Radosevich , Michael Babich , Tianhong Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Vaccines

Clinical Trial Registration Number

NCT05101356

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2700)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2700

Abstract #

TPS2700

Poster Bd #

337b

Abstract Disclosures

Similar Posters

First Author: Dale Randall Shepard

First Author: Xiaofeng Chen

First Author: Miaozhen Qiu

First Author: Timothy Jay Price